Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-[alpha] inhibitors

• Published in: PloS one 2018-04, Vol.13 (4), p.e0196281
• Main Authors: Carbo, Marlies J. G, Spoorenberg, Anneke, Maas, Fiona, Brouwer, Elisabeth, Bos, Reinhard, Bootsma, Hendrika, van der Veer, Eveline, Wink, Freke, Arends, Suzanne
• Format: Article
• Language: English
• Subjects: Ankylosing spondylitis; Development and progression; Dosage and administration; Drug therapy; Nonsteroidal anti-inflammatory agents; Patient outcomes; Tumor necrosis factor inhibitors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0196281

Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of conventional treatment for AS. However little is known about concomitant NSAID use during treatment (with TNF-[alpha] inhibitors) in daily clinical practice. Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID index were evaluated at group level and at individual patient level during 52 weeks of follow-up. Analyses were stratified for treatment regimen. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. In patients starting TNF-[alpha] inhibitors (n = 254), 79% used NSAIDs at baseline and this proportion decreased significantly to 38% at 52 weeks. ASAS-NSAID index also decreased significantly from median 65 to 0. In patients on conventional treatment (n = 139), 74% used NSAIDs at baseline with median ASAS-NSAID index of 50 and this remained stable during follow-up. At each follow-up visit, approximately half of the patients changed their type or dose of NSAIDs. GEE analysis over time showed that NSAID use was associated with AS disease activity score (p